Compare STKL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKL | LCTX |
|---|---|---|
| Founded | 1973 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.0M | 366.2M |
| IPO Year | N/A | N/A |
| Metric | STKL | LCTX |
|---|---|---|
| Price | $6.44 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $7.83 | $4.67 |
| AVG Volume (30 Days) | ★ 4.4M | 1.2M |
| Earning Date | 02-26-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $792,436,000.00 | $10,816,000.00 |
| Revenue This Year | $13.49 | $6.32 |
| Revenue Next Year | $7.13 | $124.49 |
| P/E Ratio | $150.14 | ★ N/A |
| Revenue Growth | 11.95 | ★ 24.05 |
| 52 Week Low | $3.32 | $0.37 |
| 52 Week High | $7.68 | $2.09 |
| Indicator | STKL | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 84.43 | 48.50 |
| Support Level | $4.78 | $1.65 |
| Resistance Level | $6.44 | $1.90 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 99.49 | 46.67 |
SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own propriety brands, including SOWN, Dream and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada and Others, out of which it derives maximum revenue from U.S.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.